Manhas Monica, Kalsotra Gopika, Saini Vaibhav, Kalsotra Sahil, Garg Sherry, Saraf Aditiya, Kalsotra Parmod
Post Graduate Department of Physiology, GMC, Jammu, India.
Department of ENT & HNS, S.M.G.S. Hospital, GMC, Jammu, India.
Indian J Otolaryngol Head Neck Surg. 2024 Dec;76(6):5777-5781. doi: 10.1007/s12070-024-05092-x. Epub 2024 Sep 28.
To compare treatment outcomes in allergic rhinitis patients with and without probiotics. The present study was conducted in the Out Patient Department of ENT in a Tertiary Care Hospital w.e.f. April 2023 till March 2024. Total 106 patients of allergic rhinits were included in the study and were divided randomly into 2 groups with 53 in each group. Group A was given probiotics along with standard treatment of antihistaminics and topical steroids and group B was given antihistaminics and topical steroids only. Total Nasal Symptoms Score (TNSS) of all patients was calculated at the time of enrollment and after 8 weeks post treatment. Based on the pre-treatment and post-treatment TNSS, an analysis was made whether probiotics could be an add-on therapy along with the standard treatment given for allergic rhinitis from past so many years. We conducted our study on 106 patients with mean age of 28.1 ± 8.91 years.44% were male and 56% were female. In group A pre-treatment TNSS was 8.057 + 2.307 and post treatment TNSS was 0.887 + 0.776. In group B pre-treatment TNSS was 9.45 + 0.514 and post treatment was 1.89 + 0.776. The mean post-treatment TNSS in group A was lower than the group B. This difference was statistically significant with p value of < 0.05. Based on the study we can suggest that probiotics could be a potential add-on strategy in the management of allergic rhinitis. Probiotic supplement action seems to be effective in ameliorating allergic rhinitis symptoms and improving the quality of life. However further clinical and molecular studies are required to improve our knowledge about interactions among candidate probiotics and host microbiome, cells and immune defenses, in order to create efficacious interventions.
比较使用和不使用益生菌的过敏性鼻炎患者的治疗效果。本研究于2023年4月至2024年3月在一家三级护理医院的耳鼻喉科门诊进行。共有106例过敏性鼻炎患者纳入研究,随机分为2组,每组53例。A组在使用抗组胺药和局部类固醇标准治疗的基础上加用益生菌,B组仅使用抗组胺药和局部类固醇。在入组时和治疗8周后计算所有患者的总鼻症状评分(TNSS)。根据治疗前和治疗后的TNSS,分析了多年来益生菌是否可以作为过敏性鼻炎标准治疗的附加疗法。我们对106例平均年龄为28.1±8.91岁的患者进行了研究。44%为男性,56%为女性。A组治疗前TNSS为8.057±2.307,治疗后TNSS为0.887±0.776。B组治疗前TNSS为9.45±0.514,治疗后为1.89±0.776。A组治疗后的平均TNSS低于B组。这种差异具有统计学意义,p值<0.05。基于该研究,我们可以认为益生菌可能是过敏性鼻炎管理中的一种潜在附加策略。益生菌补充剂似乎能有效改善过敏性鼻炎症状并提高生活质量。然而,需要进一步的临床和分子研究来增进我们对候选益生菌与宿主微生物群、细胞和免疫防御之间相互作用的了解,以便制定有效的干预措施。